← All trials
NCT07043634
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Jun 29, 2025
- Last posted
- Jun 29, 2025
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sarfez Pharmaceuticals, Inc.Lead sponsor
- Sarfez Pharmaceuticals, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.